ARGX-111
/ argenx
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 04, 2021
The NHance Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients.
(PubMed, Biomedicines)
- "When escalated to 1 mg/kg, a partial response was reached. Furthermore, decreased numbers of CTC (75%) possibly by the enhanced tumor cell killing witnessed the modes of action of the drug, warranting further clinical investigation of ARGX-111."
Clinical • Journal • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • FDG PET • MET
1 to 1
Of
1
Go to page
1